SVP, General Counsel and Secretary · Cue Biopharma, Inc. (CUE)

Colin Sandercock

A named executive officer of Cue Biopharma in every fiscal year CompBrief holds from FY2017 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$599,222

Salary $448,646Stock awards $0

FY2019: $625,514

5th of 5 named executive officers at Cue Biopharma by FY2025 total.

5 named officers on file for Cue Biopharma, FY2025

Colin Sandercock’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cue Biopharma’s whole pay program stands against its peers

  • Cue Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CUE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 16, 2026 (DEF 14A).

Free

Get Colin Sandercock’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Colin Sandercock compensation by year

Cue Biopharma Summary Compensation Table · all 4 fiscal years held
In US dollars, as Cue Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2025
Salary$22,917$275,000$285,000$448,646
Bonus$6,248$55,000$95,760$0
Stock awards$0$0$0$0
Option awards$1,208,659$0$244,090$149,580
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$0$220$664$996
Total$1,237,824$330,220$625,514$599,222

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cue Biopharma, Inc. DEF 14A filed March 16, 2026, accession 0001193125-26-108301, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cue Biopharma, Inc. filed document, accession 0001193125-26-108301. Every figure is read from that document and cited to the page and table it appears in. Filed March 16, 2026.

$1.2M
$330K
$626K
$599K
FY17
FY18
FY19
FY25
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option175,000—$0.98
Option37,500—$1.65
Option109,375—$1.94
Option37,500—$3.21
Option2,084—$5.01
Option7,500—$6.91

Per the Outstanding Equity Awards at Fiscal Year-End table in Cue Biopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Cue Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Daniel PasseriFormer Chief Executive Officer$1,426,183
Matteo LevisettiFormer Chief Medical Officer$1,219,364
Usman AzamPresident and Chief Executive Officer$1,185,639
Lucinda WarrenChief Financial and Business Officer$801,223
Colin Sandercock · this pageSVP, General Counsel and Secretary$599,222

The full Cue Biopharma compensation record

free company brief

This page is one person within Cue Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cue Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Colin Sandercock's compensation dossier · One-time report. No refunds.